New guidelines for the management of ankylosis spondylitis provide evidence-based disease management recommendations, which aim to be the ideal standard practice. How robust are these suggestions and are they applicable to the worldwide community of rheumatologists practicing in very different clinics around the globe?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
van der Heijde, D. et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann. Rheum. Dis. 68, 1811–1818 (2009).
Rudwaleit, M. et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann. Rheum. Dis. 68, 777–783 (2009).
van der Heijde, D. et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann. Rheum. Dis. 70, 905–908 (2011).
Braun, J. et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis. 70, 896–904 (2011).
Dougados, M. et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann. Rheum. Dis. 63, 1172–1176 (2004).
Wanders, A. et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 52, 1756–1765 (2005).
Maksymowych, W. P. et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum. 46, 766–773 (2002).
Huang, F. et al. One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum. 47, 249–254 (2002).
Inman, R. D. et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 58, 3402–3412 (2008).
van der Heijde, D. et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 58, 1324–1331 (2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
A. A. Deodhar has acted as a consultant for and has received speakers bureau honoraria as well as grant/research support from Centocor.
Rights and permissions
About this article
Cite this article
Deodhar, A. Management of AS—new guidelines in the spotlight. Nat Rev Rheumatol 7, 504–505 (2011). https://doi.org/10.1038/nrrheum.2011.111
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2011.111
